Autologous Bone Marrow Transplantation - Blog Science Connections

Natural Killer Cells and Transplantation 673
patients with minimal residual disease. Two groups of leukemic patients may
be eligible for such therapy—those in remission and those undergoing autologous
bone marrow transplantation. In both conditions, NK cells may
restrict eventual proliferation of residual leukemic cells that survived chemotherapy
or radiotherapy.
The therapeutic approach using NK cells may be implemented in two
ways. In patients who have regained some immunocompetence (patients in
remission), 1L2 administration in vivo may represent the effective therapeutic
approach. Alternatively, in patients whose immune system has been severely
depleted or in whom the presence of suppressor cells or their factors may
interfere with NK cell activation by IL2 in vivo, adoptive transfer of in vitro
IL2-activated and propagated effector cells along with 1L2 may be preferred.
ACKNOWLEDGMENT
This work was supported by grant CA 39632 from the National Cancer
Institute.
REFERENCES
1. Herberman RB, ed. Natural Cell-Mediated Immunity Against Tumors. Academic Press, New
York, 1980.
2. Lotzova E ed., Herberman RB assoc ed. Immunobiology of Natural Killer Cells, Vols. 1 and
2. CRC Press, Boca Raton, 1986.
3. Lotzova E, Savary CA, Keating MJ. Exp Hematol 1983;10:83.
4. Lotzova E, Savary CA, Keating MJ, Hester JP. In Mechanism for Cytotoxicity by NK Cells,
Herberman RB, Callewaert D, eds. Academic Press, New York, 1985:507.
5. Lotzova E, Savary CA, Herberman RB. J Immunol 1987;138:2718.
6. Lotzova E. Cancer Bulletin 1984;36:215.
7. Lotzova E, Savary CA, Herberman RB. In Natural Immunity, Cancer and Biological Response
Modification, Lotzova E, Herberman RB, eds. Basel, S. Karger, 1986:177.
8. Lotzova E, McCredie KB, Muesse L, Dicke KA, Freireich EJ. In Experimental Hematology
Today, Baum SJ, Ledney GD, eds. New York, Springer-Verlag, 1979:207.
9. Lotzova E, McCredie KB, Maroun JA, Dicke KA, Freireich EJ. Transplant Proc 1979;11:1390.
10. Lotzova E, Savary CA, Herberman RB. In Natural Immunity, Cancer and Biological Response
Modification, Lotzova E, Herberman RB, eds. Basel, S. Karger, 1986:177.
11. Lotzova E, Savary CA, Freedman RS, Bowen JM. In Gynecologic Cancer: Diagnosis and
Treatment Strategies, Rutledge FN, Freedman RS, Gershenson DM, eds. Austin, university
of Texas Press (in press).
12. Herberman RB, Balch C, Bolhuis R, Golub S, Hiserodt J, Lanier LL, Lotzova E, Phillips JH,
Riccardi C, Ritz J, Santoni A, Schmidt RE, (Jchida A, Vujanovic N. Immunology Today (in
press).